Next-Generation Immunoassay Developed for Chagas Diseases
By LabMedica International staff writers Posted on 26 Oct 2017 |
Image: Trypanosoma cruzi amastigotes in heart tissue from a patient with Chagas disease (Photo courtesy of the CDC).
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a major health and economic problem in Latin America for which no vaccine or appropriate drugs for large-scale public health interventions are yet available.
Accurate diagnosis is essential for the early identification and follows up of vector-borne cases and to prevent transmission of the disease by way of blood transfusions and organ transplantation. Diagnosis is routinely performed using serological methods, some of which require the laborious production of parasite lysates, parasite antigenic fractions or purified recombinant antigens.
Medical Parasitologists at the National University of General San Martín (Buenos Aires, Argentina) obtained human serum samples from T. cruzi-infected patients who were in the asymptomatic chronic stage of the disease without cardiac or gastrointestinal compromise (age range: 11 to 51 years old, median age: 20). Serum samples were collected from clotted blood obtained by venipuncture and analyzed for T. cruzi-specific antibodies with commercially available kits: enzyme-linked immunosorbent assay (ELISA) using total parasite homogenate and indirect hemagglutination (IHA).
The team performed a serological assessment of 27 selected epitopes and of their use in a novel multipeptide-based diagnostic method. A combination of seven of these peptides was finally evaluated in ELISA format against a panel of 199 sera samples (Chagas-positive and negative, including sera from patients with leishmaniasis). The multipeptide formulation displayed a high diagnostic performance, with a sensitivity of 96.3% and a specificity of 99.2%.
The authors concluded that their results provided a novel, robust multi-epitope formulation as a basis for the development of improved peptide-based serodiagnosis for chagas disease. In contrast with chimeric DNA constructs that encode multiepitope recombinant proteins, the fact that this diagnostic reagent is based on the combination of short peptides that can be synthesized separately and easily formulated in a mix-and-match approach, means that it can be improved successively over time with only a reasonable effort. The study was published on October 9, 2017, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
National University of General San Martín
Accurate diagnosis is essential for the early identification and follows up of vector-borne cases and to prevent transmission of the disease by way of blood transfusions and organ transplantation. Diagnosis is routinely performed using serological methods, some of which require the laborious production of parasite lysates, parasite antigenic fractions or purified recombinant antigens.
Medical Parasitologists at the National University of General San Martín (Buenos Aires, Argentina) obtained human serum samples from T. cruzi-infected patients who were in the asymptomatic chronic stage of the disease without cardiac or gastrointestinal compromise (age range: 11 to 51 years old, median age: 20). Serum samples were collected from clotted blood obtained by venipuncture and analyzed for T. cruzi-specific antibodies with commercially available kits: enzyme-linked immunosorbent assay (ELISA) using total parasite homogenate and indirect hemagglutination (IHA).
The team performed a serological assessment of 27 selected epitopes and of their use in a novel multipeptide-based diagnostic method. A combination of seven of these peptides was finally evaluated in ELISA format against a panel of 199 sera samples (Chagas-positive and negative, including sera from patients with leishmaniasis). The multipeptide formulation displayed a high diagnostic performance, with a sensitivity of 96.3% and a specificity of 99.2%.
The authors concluded that their results provided a novel, robust multi-epitope formulation as a basis for the development of improved peptide-based serodiagnosis for chagas disease. In contrast with chimeric DNA constructs that encode multiepitope recombinant proteins, the fact that this diagnostic reagent is based on the combination of short peptides that can be synthesized separately and easily formulated in a mix-and-match approach, means that it can be improved successively over time with only a reasonable effort. The study was published on October 9, 2017, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
National University of General San Martín
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia